for 5–10 minutes to 2 hours with cell suspensions containing the target cells at 0°C to 25°C, optionally followed by a per se known enrichment procedure, and evaluation of the target cell rosettes microscopically and/or by suitable visualizing or imaging devices.

6. (Amended) Method according to claim 7 [5], characterized in that the particles used in the method are coated with [ligands/]antibodies directed against the receptors/antigens listed in Table 1.

7. (Amended) Method according to claim 1 [5], characterized in that the particles used in the method are coated with antibodies directed to tumor associated antigens.

13. (Amended) Use according to claim 1 [12], wherein the adhesion molecules are E–cadherin, the growth factor receptors are EGFr, c–erbB2, IL–2 receptor, TNF receptor, the carcinoma markers are EGP2, MUC1, MUC2 & 3, PSA, PSM, GA733.2, TAG 72, 15–3 epitope, ovarian carcinoma CA– 125 epitope, the carbohydrate antigens are LeY, CEA, 15–3 epitope, the melanoma antigens are HMW 250000, gp 75/TRP–1, p95, MAG 1, 2, 3, the sarcoma antigens are TP 1 and TP 3 epitopes, the glioma antigens such as Mel–14 epitope, apoptosis associated markers are Fas FasL, p75, the motility related markers are KAT–1, AMF, the proliferation associated antigens are gp120, the differentiation associated markers are MUC 18, TA99, the drug resistance markers are MDR, MRP, the angiogenesis associated antigens are VEGFr, bFGF, [the chemekine receptors are CCR, CXCR,] the invasion–related markers are uPAR, uPA, PAI–I, TIMP1 & 2, MMP9, stromelysins, and the other antigens are cathepsin D and par–human epitope.

REMARKS

Without acquiescing to the statements made therein, Applicants hereby elect the antibodies species, and tumor associated antigens as a subspecies, with traverse. Applicants traverse the Examiner's request for election as they do not necessarily wish to be constrained to the Examiner's rationale for requesting the election.